<DOC>
	<DOCNO>NCT02070653</DOCNO>
	<brief_summary>Abdominal aortic aneurysm ( AAA ) major health problem rupture AAA common cause death Europe North America . A key limitation contemporary treatment strategy AAA lack therapy direct reduce expansion . Although surgical repair effective treatment large AAA , associate significant mortality morbidity well substantial cost . The rationale randomize control study investigate whether treatment Ticagrelor inhibit growth small abdominal aortic aneurysm .</brief_summary>
	<brief_title>The Efficacy Ticagrelor Abdominal Aortic Aneurysm ( AAA ) Expansion</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm , Abdominal</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Provision write informed consent Male female patient Age 5085 year Documented infrarenal aortic aneurysm 3549 mm Acetylsalicylic acid ( ASA ) na√Øve Short expect survival . On antiplatelet therapy . On longterm oral parenteral anticoagulant treatment . On strong inhibitor CYP3A enzyme ( Ketoconazole , Itraconazole , Voriconazole , Telithromycin , Clarithromycin , Ritonavir , Saquinavir , Nelfinavir , Indinavir , Atazanavir ) . On CYP3A ( Cytochrome P450 , family 3 , subfamily A ) substrates inducer &gt; 40mg daily dos ( Simvastatin , Lovastatin , Rifampin/rifampicin , Phenytoin , Carbamazepine , Phenobarbital ) . Known suspected connective tissue disorder ( Marfans syndrome , etc ) , infected inflammatory aneurysm , aneurysm post aortic dissection previous surgery infrarenal aorta . Increased risk bradycardia ongoing treatment bradycardia induce drug . Contraindication Ticagrelor ; hypersensitivity Ticagrelor excipients , active pathological bleeding , history intracranial hemorrhage , moderate severe hepatic impairment ( eg , ascites and/or clinical sign coagulopathy ) , haemodialysis . Known haemostatic coagulation disorder , gastrointestinal bleeding within past 6 month , increase bleeding risk due surgery trauma within 30 day . MRI exclusion criterion , : severe claustrophobia , pacemaker , metallic implant brain , cochlear implant . Metallic implant aortic region . Enrolled either another investigational drug medical device study another investigational study approve drug medical device within 30 day prior visit 1 current study . Any condition laboratory find opinion Investigator make patient unsuitable inclusion ( eg , active malignancy squamous cell basal cell skin cancer , longterm concomitant treatment nonsteroidal antiinflammatory drug ( NSAIDs ) .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Aorta</keyword>
	<keyword>Aneurysm</keyword>
	<keyword>Antiplatelet</keyword>
</DOC>